A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- 16 Jan 2020 Results (n=6501) of pooled analysis of six clinical trials (NCT00079274; NCT00096278; NCT00004931; NCT00275210; NCT00265811; NCT00112918) examining the change of outcomes over 10-year period in patients with stage 3 colon cancer who were treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database, published in the Annals of Oncology.
- 31 May 2019 Results assessing tumor stroma percentage and intrinsic subtypes in stage II/III colon cancer published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 20 Jan 2018 Results from patients receiving adjuvant FOLFOX in MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials (n=7230) presented at the 2018 Gastrointestinal Cancers Symposium